X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs VENUS REMEDIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS VENUS REMEDIES IPCA LABS/
VENUS REMEDIES
 
P/E (TTM) x 42.3 -684.6 - View Chart
P/BV x 3.2 0.2 1,621.8% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   VENUS REMEDIES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
VENUS REMEDIES
Mar-16
IPCA LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs643218 295.0%   
Low Rs50382 612.4%   
Sales per share (Unadj.) Rs254.4365.6 69.6%  
Earnings per share (Unadj.) Rs16.11.5 1,081.4%  
Cash flow per share (Unadj.) Rs29.837.9 78.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.6382.5 50.9%  
Shares outstanding (eoy) m126.2011.44 1,103.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.4 548.7%   
Avg P/E ratio x35.7101.0 35.3%  
P/CF ratio (eoy) x19.24.0 486.3%  
Price / Book Value ratio x2.90.4 750.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3001,717 4,211.9%   
No. of employees `00013.31.0 1,304.2%   
Total wages/salary Rs m6,960324 2,145.4%   
Avg. sales/employee Rs Th2,413.54,100.7 58.9%   
Avg. wages/employee Rs Th523.2318.0 164.5%   
Avg. net profit/employee Rs Th152.416.7 914.7%   
INCOME DATA
Net Sales Rs m32,1064,183 767.6%  
Other income Rs m22620 1,122.9%   
Total revenues Rs m32,3324,203 769.3%   
Gross profit Rs m4,448812 548.0%  
Depreciation Rs m1,730417 414.9%   
Interest Rs m241380 63.4%   
Profit before tax Rs m2,70335 7,701.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67518 3,730.4%   
Profit after tax Rs m2,02817 11,929.4%  
Gross profit margin %13.919.4 71.4%  
Effective tax rate %25.051.6 48.4%   
Net profit margin %6.30.4 1,554.1%  
BALANCE SHEET DATA
Current assets Rs m17,3402,771 625.8%   
Current liabilities Rs m9,5591,931 494.9%   
Net working cap to sales %24.220.1 120.8%  
Current ratio x1.81.4 126.4%  
Inventory Days Days100125 80.2%  
Debtors Days Days5754 105.8%  
Net fixed assets Rs m20,7795,328 390.0%   
Share capital Rs m252114 220.6%   
"Free" reserves Rs m24,4994,177 586.5%   
Net worth Rs m24,5534,376 561.0%   
Long term debt Rs m3,5171,911 184.1%   
Total assets Rs m39,5958,428 469.8%  
Interest coverage x12.21.1 1,119.2%   
Debt to equity ratio x0.10.4 32.8%  
Sales to assets ratio x0.80.5 163.4%   
Return on assets %5.74.7 121.7%  
Return on equity %8.30.4 2,126.3%  
Return on capital %10.56.6 158.9%  
Exports to sales %48.60-   
Imports to sales %14.220.5 69.4%   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571858 532.5%   
Fx inflow Rs m15,6170-   
Fx outflow Rs m5,828858 679.0%   
Net fx Rs m9,790-858 -1,140.6%   
CASH FLOW
From Operations Rs m2,764469 589.6%  
From Investments Rs m-1,43229 -4,903.1%  
From Financial Activity Rs m-1,591-464 343.3%  
Net Cashflow Rs m-25935 -750.1%  

Share Holding

Indian Promoters % 45.9 32.9 139.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 6,333.3%  
FIIs % 25.3 0.6 4,362.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 66.4 26.2%  
Shareholders   36,892 20,121 183.4%  
Pledged promoter(s) holding % 2.1 36.4 5.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SUN PHARMA  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  DR. REDDYS LAB  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 20, 2018 11:25 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PANACEA BIOTECH COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS